CD8A and neoplasm: Agonistic anti-CD137 mAb typically enhances CD8+ T-cell responses against immunizing peptides such as HPV E7 (49) and LCMV NP396-404 (35), staphylococcal enterotoxin A (51), and several mouse tumor cells including Ag104A, P815, MC38, and B16-F10 melanoma (51, 53).